The Science
Hereditary hair loss (androgenetic alopecia) doesn't kill your follicles outright — it starves them. Genetically sensitive follicles receive less blood flow and energy over time, producing thinner, shorter hairs until they stop entirely. Science has known for decades how to wake them up.
Photobiomodulation Therapy (PBMT) delivers targeted red laser light at precisely 650 nm to the scalp. This wavelength is absorbed by cytochrome c oxidase in the mitochondria of hair follicle cells, triggering increased ATP production and cellular activity. Dormant follicles begin producing hair again — transitioning from the resting phase (telogen) back into active growth (anagen).
The FDA has reviewed this evidence and cleared Xtrallux devices for treating androgenetic alopecia under 510(k) K222364. Multiple peer-reviewed randomized controlled trials (Lanzafame 2013/2014, Suchonwanit 2019, Liu 2019) report statistically significant terminal hair-count increases versus sham devices at 16–24 weeks.
650 nm red laser light penetrates tissue to reach follicle cells. Lasers, not LEDs, are required for consistent depth and energy concentration.
Cytochrome c oxidase absorbs the photonic energy, boosting ATP production and cellular metabolism.
Follicles shift from telogen back to anagen. Thicker, more visible hair emerges over months of consistent treatment.
More laser diodes deliver more total energy per session and more uniform coverage — the key spec separating the three Xtrallux models.
Frequently Asked
Most users report reduced shedding within 1–2 months, early new-growth signals at 3–4 months, and visible improvements between months 5–6. Continued daily use is required to maintain and enhance results.
Yes. The U.S. FDA has cleared Xtrallux devices as effective for treating androgenetic alopecia under 510(k) K222364. Multiple peer-reviewed RCTs report statistically significant terminal hair-count increases vs sham at 16–24 weeks. Individual results vary.
Yes. Xtrallux devices are designed for daily 6-minute sessions. Exceeding the recommended usage doesn't add benefit and may have a negative impact. The devices are Class 3R per IEC 60825-1 and emit no heat.
No. Xtrallux is cold laser therapy. The red light delivers no heat — any warmth you feel is from the electronics housing or your own body heat, not the laser.
Xtrallux caps cover the full scalp dome, treating frontal and crown areas simultaneously. Higher-density models (SuperPlus, TurboPro) provide more uniform coverage and may produce results faster across the entire treated area.
All three are FDA-cleared and deliver the same 650 nm red laser energy. The difference is laser density: Alpha (136), SuperPlus (276), TurboPro (316). Higher density means more uniform coverage, more total energy per session, and generally faster visible results. See the full comparison.
No. Xtrallux is FDA-cleared for mild to moderate hair loss only: Norwood-Hamilton IIa–V for men, Ludwig-Savin I-1 to II-2 for women. If your loss is advanced or due to scarring alopecia, this device is not for you — consult a hair restoration physician.
650 nm at low power has no reported adverse effects for any skin tone, but Xtrallux devices are FDA-cleared specifically for Fitzpatrick Skin Types I–IV based on the clinical data in the 510(k) submission.
Yes. Each device includes a travel case, universal AC adapter (100–240 V) and 4 international plug blades. The 18.5 Wh lithium-ion power pack is well under TSA's 100 Wh carry-on limit — carry it onboard.
Xtrallux uses the same 650 nm wavelength and laser class as professional in-clinic LLLT systems. The difference is form factor and convenience: clinic-grade therapy at home, every day, in 6 minutes.
Prime-fast shipping, Amazon's familiar checkout and customer service, and easy returns handling. You get the identical genuine Xtrallux device sold by the brand on Amazon.
Pick your laser density and check today's price on Amazon.
Shop Xtrallux on Amazon →